Real-world data on keytruda and opdivo for HPV throat cancer could shape future trials
NCT ID NCT06771674
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 662 patients with HPV-positive throat cancer that had spread or come back. Researchers wanted to see how patients were treated with pembrolizumab (Keytruda) or nivolumab (Opdivo), with or without chemotherapy, in real-world settings. The goal was to gather information on patient characteristics, treatment patterns, and outcomes to help design better clinical trials in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and nivolumab (Opdivo), with or without chemotherapy
What this could lead to
If successful, this study could help design better future trials by comparing real-world outcomes with clinical trial data.
What could go wrong
This is an observational study, not a test of a new treatment. It only looks back at existing data, so it cannot prove what works best.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States